← AGENUS INC (AGEN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
AGENUS INC (AGEN)
Biological Products, (No Diagnostic Substances) · market cap $385M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
10
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Agenus Inc. (AGEN) is a Lexington, MA-based immuno-oncology company with a market cap of ~$140M and a sprawling pipeline of checkpoint modulators, heat-shock protein-based vaccines (HSPPC-96/Oncophage), and adjuvants. The company reported $114M in 2025 revenue but carries only ~$35M in cash — roughly 2.9 months of runway — alongside $25.4M in net debt, making near-term financing an existential concern. The next formal catalyst is an August 10, 2026 earnings report.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-09-15 (est.)Phase 2 · Balstilimabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Botensilimab | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma |
| autologous human tumor-derived HSPPC-96 | Phase 3 | Renal Cell Carcinoma |
| Balstilimab | Phase 2 | Advanced Melanoma |
| AGEN2034 | Phase 2 | Advanced Cancer |
| AGEN1884 | Phase 2 | Cervical Cancer |
| AGEN1884 + AGEN2034 | Phase 2 | Cervical Cancer |
| Zalifrelimab | Phase 2 | Advanced Solid Cancers |
| HerpV and QS-21 | Phase 2 | Herpes Simplex Type 2 |
| HSPPC-96 or Oncophage | Phase 3 | Malignant Melanoma |
| HSPPC-96 | Phase 2 | Non-Small-Cell Lung Carcinoma |
Price & technical context
3-month
+138.7%
6-month
+145.0%
12-month
+116.4%
52-wk range
$2.77–$9.93
vs 50-day MA
+8.6%
vs 200-day MA
+82.1%
Realized vol
105.0%
Max drawdown
-75.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.